Molecular-targeted Therapy and Surgery May Prolong Survival of Renal Cell Carcinoma Patients with Bone Metastasis: A Multi-institutional Retrospective Study in Japan

被引：11

作者：

Kitamura, Hiroshi ^{[1
]}

Takahashi, Atsushi ^{[2
]}

Takei, Fumiyasu ^{[3
]}

Hotta, Hiroshi ^{[4
]}

Miyao, Noriomi ^{[5
]}

Shindo, Tetsuya ^{[6
]}

Igarashi, Manabu ^{[7
]}

Tachiki, Hitoshi ^{[8
]}

Kunishima, Yasuharu ^{[9
]}

Muranaka, Takashi ^{[10
]}

Shigyo, Masanori ^{[11
]}

Ikehata, Yoshinori ^{[12
]}

Masumori, Naoya ^{[13
]}

机构：

[1] Toyama Univ, Toyama, Japan

[2] Hakodate Goryoukaku Hosp, Hakodate, Hokkaido, Japan

[3] Sunagawa City Med Ctr, Sunagawa, Japan

[4] Japanese Red Cross Asahikawa Hosp, Asahikawa, Hokkaido, Japan

[5] Muroran City Gen Hosp, Muroran, Hokkaido, Japan

[6] NTT East Japan Sapporo Hosp, Sapporo, Hokkaido, Japan

[7] Takikawa Municipal Hosp, Takikawa, Hokkaido, Japan

[8] Steel Mem Muroran Hosp, Muroran, Hokkaido, Japan

[9] Obihiro Kyokai Hosp, Obihiro, Hokkaido, Japan

[10] JCHO Hokkaido Hosp, Sapporo, Hokkaido, Japan

[11] Kushiro Red Cross Hosp, Kushiro, Hokkaido, Japan

[12] Oji Gen Hosp, Tomakomai, Japan

[13] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan

来源：

ANTICANCER RESEARCH | 2016年 / 36卷 / 10期

关键词：

Kidney neoplasms; neoplasm metastasis; bone; molecular-targeted therapy; surgery; POPULATION-BASED ANALYSIS; PHASE-III TRIAL; CYTOREDUCTIVE NEPHRECTOMY; PROGNOSTIC-FACTORS; INTERFERON-ALPHA; SUNITINIB; ERA; BISPHOSPHONATES; EVEROLIMUS; CANCER;

D O I：

10.21873/anticanres.11136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To determine prognostic factors for overall survival (OS) in renal cell carcinoma (RCC) patients with bone metastasis in the targeted-therapy era. Patients and Methods: We conducted a retrospective multi-institutional review of the medical records of 149 RCC patients with bone metastasis. Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were performed to identify independent factors associated with OS. Results: The median OS was 13.4 months. In multivariate analysis, molecular-targeted therapy, nephrectomy and surgery for bone metastasis were independent prognostic factors. Bone-modifying agents (BMAs) were not associated with OS. The median OS of patients receiving molecular-targeted therapy after diagnosis of bone metastasis was significantly better than that of those who did not receive targeted therapy. Conclusion: Molecular-targeted therapy, nephrectomy and surgery for bone metastasis should be considered for RCC patients with metastasis in the bones.

引用

页码：5531 / 5536

页数：6

共 25 条

[1] Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases
Beuselinck, B.
Wolter, P.
Karadimou, A.
Elaidi, R.
Dumez, H.
Rogiers, A.
Van Cann, T.
Willems, L.
Body, J-J
Berkers, J.
Van Poppel, H.
Lerut, E.
Debruyne, P.
Paridaens, R.
Schoffski, P.
[J]. BRITISH JOURNAL OF CANCER, 2012, 107 (10) : 1665 - 1671
[2] Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
Bianchi, M.
Sun, M.
Jeldres, C.
Shariat, S. F.
Trinh, Q. -D.
Briganti, A.
Tian, Z.
Schmitges, J.
Graefen, M.
Perrotte, P.
Menon, M.
Montorsi, F.
Karakiewicz, P. I.
[J]. ANNALS OF ONCOLOGY, 2012, 23 (04) : 973 - 980
[3] Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era
Conti, Simon L.
Thomas, I-Chun
Hagedorn, Judith C.
Chung, Benjamin I.
Chertow, Glenn M.
Wagner, Todd H.
Brooks, James D.
Srinivas, Sandy
Leppert, John T.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 134 (09) : 2245 - 2252
[4] Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era
Culp, Stephen H.
Karam, Jose A.
Wood, Christopher G.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 561 - 568
[5] Local treatments for metastases of renal cell carcinoma: a systematic review
Dabestani, Saeed
Marconi, Lorenzo
Hofmann, Fabian
Stewart, Fiona
Lam, Thomas B. L.
Canfield, Steven E.
Staehler, Michael
Powles, Thomas
Ljungberg, Boerje
Bex, Axel
[J]. LANCET ONCOLOGY, 2014, 15 (12) : E549 - E561
[6] Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
Flanigan, RC
Salmon, SE
Blumenstein, BA
Bearman, SI
Roy, V
McGrath, PC
Caton, JR
Munshi, N
Crawford, ED
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) : 1655 - 1659
[7] Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
Flanigan, RC
Mickisch, G
Sylvester, R
Tangen, C
Van Poppel, H
Crawford, ED
[J]. JOURNAL OF UROLOGY, 2004, 171 (03) : 1071 - 1076
[8] Solitary bony metastasis from renal cell carcinoma - Significance of surgical treatment
Fuchs, B
Trousdale, RT
Rock, MG
[J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2005, (431) : 187 - 192
[9] Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Heng, Daniel Y. C.
Wells, J. Connor
Rini, Brian I.
Beuselinck, Benoit
Lee, Jae-Lyun
Knox, Jennifer J.
Bjarnason, Georg A.
Pal, Sumanta Kumar
Kollmannsberger, Christian K.
Yuasa, Takeshi
Srinivas, Sandy
Donskov, Frede
Bamias, Aristotelis
Wood, Lori A.
Ernst, D. Scott
Agarwal, Neeraj
Vaishampayan, Ulka N.
Rha, Sun Young
Kim, Jenny J.
Choueiri, Toni K.
[J]. EUROPEAN UROLOGY, 2014, 66 (04) : 704 - 710
[10] Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
Keizman, Daniel
Ish-Shalom, Maya
Pili, Roberto
Hammers, Hans
Eisenberger, Mario A.
Sinibaldi, Victoria
Boursi, Ben
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Peer, Avivit
Kovel, Svetlana
Sella, Avishay
Berger, Raanan
Carducci, Michael A.
[J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (07) : 1031 - 1037

← 1 2 3 →